AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, ...
AstraZeneca Plc got a rare sell rating on Thursday as Deutsche Bank AG analysts downgraded the British drugmaker, taking a more skeptical view on the company’s drug pipeline, in particular for breast ...
AstraZeneca PLC boasts strong 2024 results with $54B revenue and 14 blockbuster drugs, driven by robust growth in oncology and rare disease franchises. Key products like Farxiga, Tagrisso, and ...
AstraZeneca has outlaid up to $18.5bn in a licensing deal with China-based CSPC Pharmaceuticals to develop longer lasting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results